ATARI: A trial looking at ceralasertib for ovarian and endometrial clear cell cancers
Enrolment of participants on hold
What is the study about?
ATARI investigates whether a new type of drug could help treat people with certain types of gynaecological cancers that have come back after treatment.
Laboratory research has found that cancer cells with an abnormality (mutation) in a gene called ARID1A can be killed by a new type of drug called an ATR inhibitor. ARID1A abnormalities are more likely to be present in certain rare types of gynaecological cancers and particularly clear cell cancers of the ovaries and womb (endometrial).
Laboratory research has also shown ATR-inhibitors may also kill cancer cells without an ARID1A mutation when taken with another type of anti-cancer drug called PARP inhibitors.
ATARI will investigate whether giving people the ATR inhibitor ceralasertib, either alone or in combination with the PARP-inhibitor olaparib, can help shrink their cancer.